Pleiotropic effects of regular lipoprotein-apheresis

被引:12
|
作者
Sinzinger, Helmut [1 ]
Steiner, Sabine [2 ]
Derfler, Kurt [3 ]
机构
[1] Inst Diag & Treatment Lipid Disorders & Atheroscl, Vienna, Austria
[2] Univ Leipzig, Dept Intervent Angiol, Leipzig, Germany
[3] Med Univ Vienna, Dept Internal Med 3, Nephrol, Vienna, Austria
关键词
Endothelial function; Lipoprotein-apheresis; Pleiotropic effects; Microalbuminuria; Left ventricular ejection fraction; Homocysteine; ENDOTHELIAL PROGENITOR CELLS; SINGLE LDL APHERESIS; PLASMA-CONCENTRATIONS; DISEASE; HYPERCHOLESTEROLEMIA; MICROALBUMINURIA; VASOACTIVITY; PROGRESSION; SELECTIN; VCAM-1;
D O I
10.1016/j.atherosclerosissup.2017.05.032
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Lipoprotein(LP)-apheresis is the treatment of choice in patients suffering from severe familial hypercholesterolemia. A wide range of mechanisms has been claimed to be responsible for the known clinical benefit. Methods: Patients suffering from heterozygous familial hypercholesterolemia undergoing LP-apheresis either with direct adsorption of lipoproteins (DALI) or dextran sulfate (DS) were examined. A total volume of 10 l blood was exchanged. Non-lipid effects, mainly concerning endothelial function (circulating endothelial cells, circulating endothelial progenitor cells, flow-mediated vasodilation, microalbuminuria) as well as left ventricular ejection fraction and homocysteine were assessed. Results: A single LP-apheresis session improves paradox contractile response in statin intolerant patients, but not in those on regular statin therapy. In contrast, over a 6-months follow-up after treatment initiation, all the examined parameters (circulating endothelial cells, circulating endothelial progenitor cells, flow mediated vasodilatation, homocysteine, microalbuminuria and left ventricular ejection fraction) improved. When available, a comparison between DS vs. DALI was performed. In none of the subgroups a significant difference was noted. Discussion: These findings indicate that beyond the well known lipid/lipoprotein lowering action the broad spectrum of functional tests examined reflecting mainly endothelial function is significantly improved by LP-apheresis treatment on the long-term and seems to be a key underlying reason for the clinical improvement seen in these patients. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:122 / 127
页数:6
相关论文
共 50 条
  • [11] Lipoprotein apheresis in Austria - Reduction of cardiovascular events by regular lipoprotein apheresis treatment
    Berent, Theresa
    Derfler, Kurt
    Berent, Robert
    Sinzinger, Helmut
    ATHEROSCLEROSIS SUPPLEMENTS, 2019, 40 : 8 - 11
  • [12] LOW-DENSITY LIPOPROTEIN-APHERESIS BY DEXTRAN SULFATE-CELLULOSE ADSORPTION
    YOKOYAMA, S
    TANI, N
    KIKKAWA, T
    HAYASHI, R
    KOJIMA, T
    SATANI, M
    KAWAGUCHI, A
    HARADA, M
    TSUSHIMA, M
    YAMAMOTO, A
    ATHEROSCLEROSIS VIII, 1989, 817 : 823 - 826
  • [13] Pleiotropic effects of LDL apheresis
    Ramunni, Alfonso
    Burzo, Maria
    Verno, Lucia
    Brescia, Paola
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (05) : 53 - 55
  • [14] Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort
    Beliard, Sophie
    Gallo, Antonio
    Duchene, Emilie
    Carrie, Alain
    Bittar, Randa
    Chapman, M. John
    Bruckert, Eric
    Saheb, Samir
    ATHEROSCLEROSIS, 2018, 277 : 66 - 71
  • [15] Low density lipoprotein-apheresis decreases oxidized low density lipoproteins and monocyte adhesion to endothelial cells
    Cattin, L
    Petrucco, A
    Cazzolato, G
    Bon, GB
    Borelli, V
    Nardon, E
    Zabucchi, G
    Fonda, M
    Bordin, P
    ASAIO JOURNAL, 1997, 43 (03) : 209 - 213
  • [16] Regression of transplant coronary artery disease during chronic low-density lipoprotein-apheresis
    Park, JW
    Merz, M
    Braun, P
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1997, 16 (03): : 290 - 297
  • [17] Improvement of refractory pruritus after lipoprotein-apheresis in arthrogryposis-renal failure-cholestasis syndrome
    Rosales, A.
    Munoz, M.
    Madrid, A.
    Chocron, S.
    Hernandez, J. M.
    Ariceta, G.
    JOURNAL OF CLINICAL APHERESIS, 2018, 33 (03) : 401 - 403
  • [18] Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run
    Gross, E.
    Hohenstein, B.
    Julius, U.
    ATHEROSCLEROSIS SUPPLEMENTS, 2015, 18 : 226 - 232
  • [19] Meaning of low-density lipoprotein-apheresis for hypercholesterolemic patients at high risk for recurrence of coronary heart disease
    Koga, N
    THERAPEUTIC APHERESIS, 2002, 6 (05): : 372 - 380
  • [20] First steps toward the establishment of a German low-density lipoprotein-apheresis registry: Recommendations for the indication and for quality management
    Mueller, GA
    Schettler, V
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 172 - 172